Summary
35.26 -0.63(-1.76%)09/06/2024
Vertex Inc (VERX)
Vertex Inc (VERX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.59 | -8.70 | -2.52 | 6.14 | 19.12 | 62.26 | 0.00 | 47.35 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 35.26 | |
| Open | 36.09 | |
| High | 36.16 | |
| Low | 35.14 | |
| Volume | 354,817 | |
| Change | -0.57 | |
| Change % | -1.59 | |
| Avg Volume (20 Days) | 503,844 | |
| Volume/Avg Volume (20 Days) Ratio | 0.70 | |
| 52 Week Range | 20.48 - 40.05 | |
| Price vs 52 Week High | -11.96% | |
| Price vs 52 Week Low | 72.17% | |
| Range | -2.30 | |
| Gap Up/Down | -0.39 | |
Fundamentals | ||
| Market Capitalization (Mln) | 5,482 | |
| EBIDTA | 14,393,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 25.17 | |
| Book Value | 1.5090 | |
| Earnings Per Share | -0.0040 | |
| EPS Estimate Current Quarter | 0.0500 | |
| EPS Estimate Next Quarter | 0.0500 | |
| EPS Estimate Current Year | 0.2800 | |
| EPS Estimate Next Year | 0.2700 | |
| Diluted EPS (TTM) | -0.0040 | |
| Revenues | ||
| Profit Marging | -0.0015 | |
| Operating Marging (TTM) | 0.0114 | |
| Return on asset (TTM) | 0.0051 | |
| Return on equity (TTM) | -0.0028 | |
| Revenue TTM | 413,436,000 | |
| Revenue per share TTM | 2.8090 | |
| Quarterly Revenue Growth (YOY) | 0.1700 | |
| Quarterly Earnings Growth (YOY) | -0.9610 | |
| Gross Profit (TTM) | 209,278,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 12.0778 | |
| Revenue Enterprise Value | 6.5071 | |
| EBITDA Enterprise Value | 67.0962 | |
| Shares | ||
| Shares Outstanding | 40,772,700 | |
| Shares Float | 8,949,703 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 2.81 | |
| Institutions (%) | 67.90 | |
09/06 16:05 EST - globenewswire.com
Vertex to Present at Goldman Sachs Conference
KING OF PRUSSIA, Pa., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a global provider of tax technology solutions, today announced that David DeStefano, Chief Executive Officer, and John Schwab, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs Communacopia + Technology Conference on Monday, September 9, 2024 at 9:30 AM Pacific Time.
Vertex to Present at Goldman Sachs Conference
KING OF PRUSSIA, Pa., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a global provider of tax technology solutions, today announced that David DeStefano, Chief Executive Officer, and John Schwab, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs Communacopia + Technology Conference on Monday, September 9, 2024 at 9:30 AM Pacific Time.
09/05 01:00 EST - seekingalpha.com
Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced
Vertex Pharmaceuticals, a leader in Cystic Fibrosis treatment, reported strong financials in Q2 but faces limited growth in CF due to high market penetration. Despite a GAAP net loss in Q2, Vertex remains highly profitable, with promising assets like Casgevy and Suzetrigine poised for future growth. Vertex's high valuation ratios suggest potential overvaluation, but its focused pipeline and blockbuster potential justify optimism for significant long-term revenue growth.
Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced
Vertex Pharmaceuticals, a leader in Cystic Fibrosis treatment, reported strong financials in Q2 but faces limited growth in CF due to high market penetration. Despite a GAAP net loss in Q2, Vertex remains highly profitable, with promising assets like Casgevy and Suzetrigine poised for future growth. Vertex's high valuation ratios suggest potential overvaluation, but its focused pipeline and blockbuster potential justify optimism for significant long-term revenue growth.
09/04 07:05 EST - globenewswire.com
Vertex Completes Acquisition of ecosio
KING OF PRUSSIA, Pa., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced that it has completed the acquisition of ecosio, a leading B2B integration provider specializing in electronic data interchange (EDI) and e-invoicing, as of August 30, 2024.
Vertex Completes Acquisition of ecosio
KING OF PRUSSIA, Pa., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced that it has completed the acquisition of ecosio, a leading B2B integration provider specializing in electronic data interchange (EDI) and e-invoicing, as of August 30, 2024.
09/03 13:21 EST - zacks.com
Surging Earnings Estimates Signal Upside for Vertex (VERX) Stock
Vertex (VERX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Surging Earnings Estimates Signal Upside for Vertex (VERX) Stock
Vertex (VERX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
09/02 13:45 EST - zacks.com
3 Reasons Why Growth Investors Shouldn't Overlook Vertex (VERX)
Vertex (VERX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
3 Reasons Why Growth Investors Shouldn't Overlook Vertex (VERX)
Vertex (VERX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
09/02 10:51 EST - zacks.com
Scoop up These 4 GARP Stocks to Receive Handsome Returns
The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. HCA, ADBE, WRB and VERX are some stocks that hold promise.
Scoop up These 4 GARP Stocks to Receive Handsome Returns
The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. HCA, ADBE, WRB and VERX are some stocks that hold promise.
08/30 05:50 EST - fool.com
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
Vertex enjoys a monopoly that could soon grow stronger. The company could have multiple potential blockbuster drugs on the way.
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
Vertex enjoys a monopoly that could soon grow stronger. The company could have multiple potential blockbuster drugs on the way.
08/29 08:00 EST - businesswire.com
Jupiter Endovascular Receives FDA Approval for U.S. Pivotal Study of Vertex Pulmonary Embolectomy System Using Endoportal Control
MENLO PARK, Calif.--(BUSINESS WIRE)-- #FDA--FDA approves U.S. pivotal trial of Jupiter Endovascular pulmonary embolism system with Endoportal Control technology.
Jupiter Endovascular Receives FDA Approval for U.S. Pivotal Study of Vertex Pulmonary Embolectomy System Using Endoportal Control
MENLO PARK, Calif.--(BUSINESS WIRE)-- #FDA--FDA approves U.S. pivotal trial of Jupiter Endovascular pulmonary embolism system with Endoportal Control technology.
08/21 08:54 EST - seekingalpha.com
Vertex, Inc.: Growth Momentum Continues With FCF Conversion Rates Inflecting Upwards
Bullish on Vertex, Inc. due to strong growth outlook. 2Q24 results show solid growth across the board, with a strong FCF conversion rate. Ecosio acquisition is accretive, improving product offering, and expected to drive growth in the future.
Vertex, Inc.: Growth Momentum Continues With FCF Conversion Rates Inflecting Upwards
Bullish on Vertex, Inc. due to strong growth outlook. 2Q24 results show solid growth across the board, with a strong FCF conversion rate. Ecosio acquisition is accretive, improving product offering, and expected to drive growth in the future.
08/16 13:45 EST - zacks.com
Is Vertex (VERX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Vertex (VERX) could produce exceptional returns because of its solid growth attributes.
Is Vertex (VERX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Vertex (VERX) could produce exceptional returns because of its solid growth attributes.
08/15 07:40 EST - investorplace.com
3 Stocks to Sell Before the Market Crash Resumes
Markets have yet to recover from the sudden dip they experienced at the start of the month, revealing how poor economic data can spook investors and impact stocks. The drop and rather slow recovery suggest investors remain cautious and may consider which stocks to sell now ahead of a potential trend resumption.
3 Stocks to Sell Before the Market Crash Resumes
Markets have yet to recover from the sudden dip they experienced at the start of the month, revealing how poor economic data can spook investors and impact stocks. The drop and rather slow recovery suggest investors remain cautious and may consider which stocks to sell now ahead of a potential trend resumption.
08/09 05:31 EST - zacks.com
The Zacks Analyst Blog Vertex Pharmaceuticals CRISPR and Moderna
Vertex Pharmaceuticals CRISPR and Moderna are included in this Analyst Blog.
The Zacks Analyst Blog Vertex Pharmaceuticals CRISPR and Moderna
Vertex Pharmaceuticals CRISPR and Moderna are included in this Analyst Blog.
08/07 19:12 EST - businesswire.com
Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY™ (exagamglogene autotemcel), from today. The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY's use in the NHS. The United Kingdom (U.K.) Medicines and Healthcare p.
Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY™ (exagamglogene autotemcel), from today. The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY's use in the NHS. The United Kingdom (U.K.) Medicines and Healthcare p.
08/07 12:35 EST - seekingalpha.com
Vertex, Inc. (VERX) Q2 2024 Earnings Call Transcript
Vertex, Inc. (NASDAQ:VERX ) Q2 2024 Results Conference Call August 7, 2024 8:30 AM ET Company Participants Joe Crivelli - VP, IR David DeStefano - President and CEO John Schwab - CFO Conference Call Participants Brad Reback - Stifel Joshua Reilly - Needham Rob Oliver - Baird Chris Quinter - Morgan Stanley Steve Enders - Citi Daniel Jester - BMO Capital Markets Adam Hotchkiss - Goldman Sachs Alex Sklar - Raymond James Patrick Walravens - Citizens JMP Securities Jake Roberge - William Blair Operator Good morning. And welcome to the Vertex Inc. Second Quarter 2024 Earnings Conference Call.
Vertex, Inc. (VERX) Q2 2024 Earnings Call Transcript
Vertex, Inc. (NASDAQ:VERX ) Q2 2024 Results Conference Call August 7, 2024 8:30 AM ET Company Participants Joe Crivelli - VP, IR David DeStefano - President and CEO John Schwab - CFO Conference Call Participants Brad Reback - Stifel Joshua Reilly - Needham Rob Oliver - Baird Chris Quinter - Morgan Stanley Steve Enders - Citi Daniel Jester - BMO Capital Markets Adam Hotchkiss - Goldman Sachs Alex Sklar - Raymond James Patrick Walravens - Citizens JMP Securities Jake Roberge - William Blair Operator Good morning. And welcome to the Vertex Inc. Second Quarter 2024 Earnings Conference Call.
08/07 09:21 EST - zacks.com
Vertex (VERX) Tops Q2 Earnings and Revenue Estimates
Vertex (VERX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.08 per share a year ago.
Vertex (VERX) Tops Q2 Earnings and Revenue Estimates
Vertex (VERX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.08 per share a year ago.
08/07 07:07 EST - globenewswire.com
Vertex Acquires ecosio To Accelerate Global E-Invoicing Compliance
Delivering a Seamlessly Connected Global Platform to Manage Continuous Compliance Delivering a Seamlessly Connected Global Platform to Manage Continuous Compliance
Vertex Acquires ecosio To Accelerate Global E-Invoicing Compliance
Delivering a Seamlessly Connected Global Platform to Manage Continuous Compliance Delivering a Seamlessly Connected Global Platform to Manage Continuous Compliance
08/07 07:06 EST - globenewswire.com
Vertex Announces Second Quarter 2024 Financial Results
KING OF PRUSSIA, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its second quarter ended June 30, 2024.
Vertex Announces Second Quarter 2024 Financial Results
KING OF PRUSSIA, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its second quarter ended June 30, 2024.
08/06 04:31 EST - fool.com
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Vertex Pharmaceuticals is a rare-disease drugmaker with over $10 billion in annual sales. The company's lead drug is the only available treatment for cystic fibrosis, a life-threatening progressive disease.
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Vertex Pharmaceuticals is a rare-disease drugmaker with over $10 billion in annual sales. The company's lead drug is the only available treatment for cystic fibrosis, a life-threatening progressive disease.
08/02 14:48 EST - fool.com
Vertex Raises Guidance Despite Q2's Bottom-Line Losses
Product revenues increased by 6% to $2.65 billion, in line with market expectations. Management raised full-year product revenue guidance by $100 million.
Vertex Raises Guidance Despite Q2's Bottom-Line Losses
Product revenues increased by 6% to $2.65 billion, in line with market expectations. Management raised full-year product revenue guidance by $100 million.
08/02 13:48 EST - benzinga.com
Vertex Pharmaceuticals Lifts Annual Guidance, Positive Growth For Its Cystic Fibrosis Franchise And Pain Management Pipeline
Thursday, Vertex Pharmaceuticals Incorporated VTRX reported second-quarter revenues of $2.65 billion, almost in line with the consensus of estimate of $2.66 billion.
Vertex Pharmaceuticals Lifts Annual Guidance, Positive Growth For Its Cystic Fibrosis Franchise And Pain Management Pipeline
Thursday, Vertex Pharmaceuticals Incorporated VTRX reported second-quarter revenues of $2.65 billion, almost in line with the consensus of estimate of $2.66 billion.